Pandemic Brings Hundreds Of U.S. Clinical Trials To A Halt, page-8

Obviously a different treatment/ company, but the FDA’s Oncology director’s comment is relevant .

https://www.precisiononcologynews.com/cancer/seattle-genetics-tukysa-nabs-fda-approval-metastatic-her2-positive-breast-cancer In approving the drug, Richard Pazdur, director of the FDA’s Oncology Center of Excellence, highlighted that tucatinib was approved four months ahead of the expected approval date for the drug, which demonstrates that the agency is working hard to ensure that the pandemic isn't negatively impacting patients' access to novel cancer drugs. "We recognize that patients with cancer constitute a vulnerable population at risk of contracting the coronavirus disease," Pazdur said in a statement. "In this critical time, we remain steadfast in our commitment to patients with cancer and doing everything we can to expedite oncology product development."